From patients to discoveries

CRYOSTEM, a national cohort dedicated to the complications of Hematopoietic Stem Cell Transplantation (HSCT)

Biological resources

The patient-biobank duo: the two pillars of novel precision medicine

CRYOSTEM biospecimen collection

Throughout the year, CRYOSTEM encourages researchers to apply for samples access


CRYOSTEM supports fundamental, translational and clinical research projects in the field of HSCT complications


CRYOSTEM develops tailor-made biobanking network solutions for innovative projects and medical research 


A collection unique in Europe

Launched within the framework of Investments for the Future by the National Research Agency (ANR), at the heart of the French Government’s Plan Cancer and supported by the National Cancer Institute (INCa), the CRYOSTEM’s project was initiated in 2011 under the auspices of the Francophone Society of Marrow Transplantations and Cellular Therapy (SFGM-TC) to accelerate research in the area of complications of Hematopoietic Stem Cell Transplantation (HSCT), previously called bone marrow transplantation. Today, CRYOSTEM brings together all French transplant units, 28 Biological Resource Centers (CRB) as well as more than 400 French research and healthcare players in the field of severe blood diseases.


CRYOSTEM partnering centers
(transplant units and biological resource centers)


Today the CRYOSTEM community offers academic and industrial research teams, a collection of almost 200 000 samples to address life-threatening complications of HSCT.

Claire Fontenille
CRYOSTEM regulatory and operational manager



CRYOSTEM is a wonderful opportunity for researchers to better understand the biological mechanisms, to improve the prevention and the management of the complications of HSCT.

Dr. Claire Galambrun
Department of Pediatric Hematology,
The Timone Hospital

CRYOSTEM could play a significant role to predict the transplant toxicity.

Dr. Boris Calmels
Department of Hematology and Cell Therapy
Institut Paoli-Calmettes,
Founding Member of CRYOSTEM

Throughout the year, CRYOSTEM encourages researchers to apply to gain access to the collection.

Dr. Emilie Robert
CRYOSTEM strategy and development manager

What interests us it is being able to discriminate early before transplantation between patients who are going to benefit from the treatment.

Pr. Régis Peffault de Latour
Department of Hematology,
The Saint Louis Hospital,
Founding Member of CRYOSTEM

An informed patient is a better armed patient : at U2T, we use games to increase patients awareness of the HSCT complications.

Laurence Caymaris
Nurse Supervisor
Department of Onco-Hematology,
Institut Paoli-Calmettes


of transplanted patients in France

  • 5 901 Recipients
  • 2 418 Donors
  • 17 774 Sampling
  • 51 012 Samples (200 391 aliquots)
  • 7 316 Cleared aliquots



Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites. Nature Communications. 2019 Dec 13;10(1):5695. doi: 10.1038/s41467-019-13498-3.


CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood. 2015 Mar 12;125(11):1830-9. doi: 10.1182/blood-2014-09-599159.

SOCIÉ G. ET AL., 2014

Current issues in chronic graft-versus-host disease. Blood. 2014 Jul 17;124(3):374-84. doi:10.1182/blood-2014-01-514752.

DONG S. ET AL., 2013

Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. Blood. 2013 Sep 5;122(10):1802-12. doi: 10.1182/blood-2013-02-482539.


CRYOSTEM is listed as a biobanking expert at Labtoo

CRYOSTEM, a new model of biobanking networks